Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TER-1754 in Hereditary Hemorrhagic Telangiectasia
NCT07255846Phase 1Withdrawn
- Start
- Dec 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TER-1754 in hereditary hemorrhagic telangiectasia (HHT) (4 arms). Primary endpoints: Safety and Tolerability of TER-1754 at 48 weeks, Maximum Tolerated Dose (MTD) and/or Maximum Administrated Dose (MAD) of TER-1754 at 28 days and 1 more. Planned start Dec 2025; status: withdrawn.
02
Drugs
TER-1754
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT07255846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07255846.